Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina

Medicinski Glasnik

Volumn 8, Issue 1, 2011, Pages 84-89

  Semiz, Sabina ^a   Dujić, Tanja ^a   Ostanek, Barbara ^b   Prnjavorac, Besim ^a,c   Bego, Tamer ^a   Malenica, Maja ^a   Mlinar, Barbara ^b   Marc, Janja ^b   Čaušević, Adlija ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c General Hospital Te anj   (Bosnia and Herzegovina)

Author keywords

Bosnian; CYP3A4; CYP3A5; Cytochrome P450; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; AGED; ALLELE; ARTICLE; BOSNIA AND HERZEGOVINA; DNA POLYMORPHISM; FEMALE; GENETIC LINKAGE; GENOTYPE; HUMAN; INCIDENCE; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; POPULATION GENETICS;

BOSNIA-HERZEGOVINA; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC;

EID: 79551713871     PISSN: 18400132     EISSN: 18402445     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006; 57:119-37. (Pubitemid 43261982)
2. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 52(21):2211-21.
3. Lynch T, Price A. The effect of Cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007; 76:391-6. (Pubitemid 47219454)
4. Hu YF, He J, Chen GL, Wang D, Liu ZQ, Zhang C, Duan LF, Zhou HH. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005; 353:187-92.
5. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG. Genetic polymorphisms of drug-metabolising enzymes CYP2D6, CYP2C9, CYP2C19, and CYP3A5 in the Geek population. Fundament Clin Pharmacol 2007; 21:419-26. (Pubitemid 47084032)
6. Bradford LD. CYP2D6 allele frequency in Europen Caucasians, Asians, Africans, and their descendants. Pharmacogenomics 2002; 3:229-43. (Pubitemid 34223859)
7. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10:373-88. (Pubitemid 30433571)
8. Evans WE, Relling MV. Pharmacogenetics: translating functional genomics into rational therapeutics. Science 1999; 286:487-91.
9. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283:1552-62. (Pubitemid 28016533)
10. Watkins PB. Cyclosporine and liver transplantation: will the midazolam test make blood level monitoring obsolete? Hepatology 1995; 22:994-96.
11. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology & Toxicology 1999; 39:1-17. (Pubitemid 29222549)
12. García-Martín E, Martínez C, Pizarro RM, García-Gamito FJ, Gullsten H, Raunio H, Agúndez JA. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002; 71:196-204.
13. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68:82-91. (Pubitemid 30609830)
14. Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005; 338:299-305. (Pubitemid 41540570)
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-91. (Pubitemid 32268418)
16. King BP, Leathart JB, Mutch E, Williams FM, Daly AK. CYP3A5 phenotype genotype correlations in a British population. Br J Clin Pharmacol 2003; 55:625-9. (Pubitemid 36783207)
17. Dally H, Edler L, Jäger B, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Schulz V, Kayser K, Bartsch H, Risch A. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 2003; 13:607-18. (Pubitemid 37311147)
18. Wojnowski L, Hustert E, Klein K, Goldammer M, Haberl M, Kirchheiner J, Koch I, Klattig J, Zanger U, Brockmöller J. Re: modiication of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 2002; 94:630-61.
19. Yamada Y, Matsuo H, Watanabe S, Kato K, Yajima K, Hibino T, Yokoi K, Ichihara S, Metoki N, Yoshida H, Satoh K, Nozawa Y. Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus. Intern J Mol Med 2007; 20:703-7.
20. Miao J, Jin Y, Marunde RL, Kim S, Quinney S, Radovich M, Li L, Hall SD. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J 2009; 9:319-26.
21. Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 2007; 8:703-12. (Pubitemid 47288971)
22. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM. Sex is a major determinant of CYP3A4 expression in Human liver. Hepatology 2003; 38:978-88. (Pubitemid 37221681)
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
24. Zhao JH. 2LD, GENECOUNTING and HAP: Computer programs for linkage disequilibrium analysis. Bioinformatics 2004; 20:1325-6.
25. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Therap 1999; 66:288-94. (Pubitemid 29451761)
26. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48:1668-71.
27. Quaranta S, Chevalier D, Bourgarel-Rey V, Allorge D, Solas C, Lo-Guidice JM, Sampol-Manos E, Vacher-Coponat H, Moal V, Broly F, Lhermitte M, Lacarelle B. Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in French popultion. Toxicol Lett 2006; 164:177-84.
28. Kivistö KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004;14:523-5. (Pubitemid 39100004)
29. First MR, Schroeder TJ, Monaco AP, Simpson MA, Curtis JJ, Armenti VT. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulation. Clin Transplant 1996; 10(1Pt1):55-9. (Pubitemid 26076429)
30. Ware N, MacPhee IA. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation. Curr Opin Mol Ther 2010; 12:270-83.
31. Kniepeiss D, Renner W, Trummer O, Wagner D, Wasler A, Khoschsorur GA, Truschnig-Wilders M, Tscheliessnigg KH. The role of CYP3A5 genotypes in dose requirements of tarolimus and everolimus after heart transplantation. Clin Transplant 2009 [Epub ahead of print]
32. Zhao Y, Zhai D, He H, Li T, Chen X, Ji H. Effects of CYP3A5, MDR1, and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort. Eur J Clin Pharmacol 2009; 65:579-84.
33. Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, Chun BG, Shin JG, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006; 80:646-56.
34. Zhou X, Barber WH, Moore CK, Tee LY, Aru G, Harrison S, Mangilog B, McDaniel DO. Frequency distribution of cytochrome P450 3A4 gene polymorphism in ethnic populations and in transplant recipients. Res Commun Mol Pharmacol 2006; 119:89-104. (Pubitemid 47579203)